Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda
March 22 2023 - 4:05PM
Business Wire
Inogen, Inc. (Nasdaq: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced the appointment of Tom West to Inogen’s
Board of Directors, effective April 1, 2023. The company also
announced that Kristen Miranda, who has served as a director since
March 2021, will retire as a member of the Board of Directors,
effective March 31, 2023.
“We are pleased to welcome Tom West to the Inogen Board. Tom
brings additional general management and operational experience to
the Inogen Board with his history of leadership and business
success in medical technology and life sciences healthcare spaces,”
said Elizabeth Mora, Chairperson of the Board. “Under the
leadership of Nabil Shabshab, Inogen’s President and CEO, we have
made significant progress in rebuilding Inogen into a MedTech
company that is capable of delivering durable growth as we
successfully execute on our strategic initiatives, advance our
prescriber growth strategy and drive productivity and efficiency of
our commercial operations. The addition of Tom West will further
elevate the partnership between the Board and the executive team to
advance Inogen’s transformation into a global respiratory care
leader.”
“On behalf of the Board of Directors, I would also like to thank
Kristen Miranda for her commitment and many valuable contributions
to the Board,” said Ms. Mora. "She has brought a lot of experience
and thought partnership around the healthcare space and channel
dynamics, specifically around the aspects of consumer health.”
Tom West serves as President and Chief Executive Officer and is
an executive Director of the Board of Nalu Medical, Inc., a
privately held medical technology company focused on
neurostimulation to treat chronic intractable pain. He joined Nalu
in August 2022. Before joining Nalu, Mr. West served from 2019 to
2022 as President, Chief Executive Officer and Director at
Intersect ENT, Inc., a publicly traded medical device and drug
delivery company in the sinus surgery space. Intersect ENT was
acquired by Medtronic in May of 2022 doubling its enterprise value
in less than three years despite the COVID pandemic. Prior to
Intersect, Mr. West served as Worldwide President, Diagnostic
Solutions at Hologic from 2015 to 2019. Mr. West began his
healthcare career at Johnson & Johnson where he assumed roles
of increasing responsibility over a twenty-three-year tenure
including Worldwide President of Strategy and Business Development
for the J&J Family of Diabetes Solutions Companies, Division
President of LifeScan North America and Division President of
LifeScan Europe, Middle East and Africa.
Mr. West served as an independent member of the Board of
Directors of publicly traded Orthofix from 2021 to 2023. He has
also been a member of the Board of medical technology trade
associations, AdvaMed and Biocom California. Mr. West received a
B.A. in Politics and Economics from Princeton University and an MBA
from the University of Pennsylvania, Wharton School.
“I am thrilled to have the opportunity to advance Inogen’s
transformation into a global respiratory care leader,” said Tom
West. “Inogen has been an industry innovator, I look forward to
adding my operating experience accelerating growth opportunities to
help the Company enhance the value it delivers to its patients,
customers and shareholders.”
In connection with the appointment, Mr. West will be joining the
Compliance Committee as well as the Nominating and Governance
Committee of the Board.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical
technology company offering innovative respiratory products for use
in the homecare setting. Inogen supports patient respiratory care
by developing, manufacturing, and marketing innovative
best-in-class portable oxygen concentrators used to deliver
supplemental long-term oxygen therapy to patients suffering from
chronic respiratory conditions. Inogen partners with patients,
prescribers, home medical equipment providers, and distributors to
make its oxygen therapy products widely available allowing patients
the chance to remain ambulatory while managing the impact of their
disease.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements with respect to the
announced changes to Inogen’s board of directors; statements
concerning or implying Inogen’s future financial performance;
statements regarding Inogen’s goals and potential, including the
potential for Inogen to achieve durable growth; statements
regarding the partnership between Inogen’s board of directors and
management; the ability of management and board of directors
personnel to contribute to the execution of Inogen’s strategic
plans and goals; and the ability of Inogen to become a prominent
leader in respiratory care. Any statements contained in this
communication that are not statements of historical fact may be
deemed to be forward-looking statements. Words such as “believes,”
“anticipates,” “plans,” “expects,” “will,” “intends,” “potential,”
“possible,” and similar expressions are intended to identify
forward-looking statements. Forward-looking statements are subject
to numerous risks and uncertainties that could cause actual results
to differ materially from currently anticipated results, including
but not limited to, risks related to its announced management and
organizational changes, and risks arising from the possibility that
Inogen will not realize anticipated future financial performance or
strategic goals. In addition, Inogen's business is subject to
numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of its products;
competition; its sales, marketing and distribution capabilities;
its planned sales, marketing, and research and development
activities; interruptions or delays in the supply of components or
materials for, or manufacturing of, its products; seasonal
variations; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
Inogen’s business operating results are contained in its Annual
Report on Form 10-K for the period ended December 31, 2021, and in
its other filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof.
Inogen disclaims any obligation to update these forward-looking
statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230322005287/en/
Agnes Lee ir@inogen.net
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Apr 2024 to May 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From May 2023 to May 2024